4'-[4,5-Dihydro-4-[(2-methoxyethoxy)methyl]-5-oxo-1H-1,2,4-triazol-1-yl]-N-(3,4-dimethyl-5-isoxazolyl)[1,1'-biphenyl]-2-sulfonamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4'-[4,5-Dihydro-4-[(2-methoxyethoxy)methyl]-5-oxo-1H-1,2,4-triazol-1-yl]-N-(3,4-dimethyl-5-isoxazolyl)[1,1'-biphenyl]-2-sulfonamide
• 英文别名: N-(3,4-dimethyl-1,2-oxazol-5-yl)-2-[4-[4-(2-methoxyethoxymethyl)-5-oxo-1,2,4-triazol-1-yl]phenyl]benzenesulfonamide
• 化学式: C₂₃H₂₅N₅O₆S
• 分子量: 499.547
• InChiKey: IDJDWFVKYXCJEQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  35
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  135
• 氢给体数：
  1
• 氢受体数：
  9

文献信息

• [EN] SUBSTITUTED BIPHENYL ISOXAZOLE SULFONAMIDES<br/>[FR] SULFONAMIDES DE BIPHENYL ISOXAZOLE SUBSTITUES
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：WO1997033886A1

  公开（公告）日：1997-09-18

  (EN) Compounds of formula (I) inhibit the activity of endothelin. The symbols R1, R2, Q, K, J, $g(a), $g(b), p, R11, R12, R13, R14, X, Y, R3 and R4 are defined herein.(FR) Les composés de formule (I) inhibent l'activité de l'endothéline. Les symboles R1, R2, Q, K, J, $g(a), $g(b), p, R11, R12, R13, R14, X, Y, R3 et R4 sont définis dans le descriptif.
• [EN] PHARMACEUTICAL AND VETERINARY USES OF ENDOTHELIN ANTAGONISTS<br/>[FR] UTILISATIONS PHARMACEUTIQUES ET VETERINAIRES D'ANTAGONISTES DE L'ENDOTHELINE ET APPLICATIONS ASSOCIEES
  申请人：TEXAS BIOTECHNOLOGY CORP

  公开号：WO2001049289A1

  公开（公告）日：2001-07-12

  Pharmaceutical and veterinary uses of endothelin antagonists are provided. In particular, methods of treatment of laminitis, such as equine and bovine laminitis, by administration of one or more endothelin antagonists are provided. Methods of treatment, prevention, or amelioration of one or more symptoms of menopause; osteoporosis and metabolic bone disorders; climacteric disorders including hot flushes or flashes, abnormal clotting patterns, urogenital discomfort and increased incidence of cardiovascular disease, and other disorders associated with the reduction in ovarian function in women; pre-eclampsia; and control and management of labor during pregnancy by administration of endothelin antagonists are also provided.